Newsroom
Sorted by: Latest
-
Law Offices of Howard G. Smith Encourages Telix Pharmaceuticals Limited (TLX) Shareholders To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TELIX PHARMACEUTICALS LIMITED (TLX), CONTACT THE LAW OFFICES OF...
-
Riassunto: PUMA rilancia la rivista dell'azienda CATch UP per presentare il meglio del marchio
HERZOGENAURACH, Germania--(BUSINESS WIRE)--L'azienda di abbigliamento e di equipaggiamento sportivo PUMA ha rilanciato la sua rivista aziendale online CATch UP per offrire a giornalisti, investitori, rivenditori, atleti e appassionati di sport una finestra sull'universo PUMA e informazioni sulle nuove priorità strategiche dell'azienda, nel momento in cui il brand inizia il suo percorso di trasformazione. La rivista online, disponibile all'indirizzo puma-catchup.com, è stata sottoposta a un proc...
-
プーマが企業誌「CATch UP」をリニューアルし、ブランドの魅力を発信
ドイツ、ヘルツォーゲンアウラハ--(BUSINESS WIRE)--(ビジネスワイヤ) -- スポーツブランドのプーマは、オンライン企業誌「CATch UP」をリニューアルしました。本誌は、ブランド変革の歩みを始めるにあたり、ジャーナリスト、投資家、小売業者、アスリート、そしてスポーツ愛好家に向け、同社の新たな戦略的優先事項への洞察およびプーマの世界を紹介する場を提供するものです。 このオンラインマガジン(puma-catchup.comで閲覧可能)は、ビジュアルを一新し、プーマを世界トップ3のスポーツブランドとして確立するために行なっている戦略的優先事項に加え、同社のイノベーション、スポーツ、歴史、企業文化を紹介するストーリーに焦点を当てます。 「75年以上にわたる歴史と数々の素晴らしいイノベーションを誇るプーマには、より多くの人々と共有すべき興味深いストーリーや歴史的な逸話が数多くあります」と、プーマのコミュニケーション部門シニアディレクターであるケルスティン・ノイバーは述べています。「PUMA CATch UPを通じて、私たちはこのようなストーリーを、当社に関心を持つすべての方...
-
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Freeport-McMoRan Inc. Investors – FCX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Freeport-McMoRan Inc. (NYSE: FCX) between February 15, 2022 and September 24, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Freeport-McMoRan investors under the federal securities laws. To join the Freeport-McMoRan class action, go to https://rosenlegal.com/submit-form/?case_id=45553 o...
-
DCXM ALERT: Kirby McInerney LLP Reminds DexCom, Inc. Investors of Important Deadline in Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until December 26, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit Abo...
-
FLY ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Firefly Aerospace Investors
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit – Diamond v. Firefly Aerospace Inc et al. – has been filed on behalf of investors who acquired Firefly Aerospace Inc. (“Firefly” or the “Company”) (NASDAQ:FLY) securities during the Company’s initial public offering (the “IPO”) conducted on or about August 7, 2025 and/or between August 7, 2025 through September 29, 2025, inclusive (“the Class Period”). If you suffered a loss on your Firefly inve...
-
proteanTecs、GM & カントリーマネージャーに小嶋範孝氏が就任 新たに日本オフィスを開設
横浜、日本--(BUSINESS WIRE)--(ビジネスワイヤ) -- 半導体のヘルスおよび性能モニタリング分野で先進的な解析ソリューションを提供するグローバルリーダー、proteanTecs® は、日本市場での事業拡大を目的として、神奈川県横浜市に、新たに日本オフィスを開設しました。 併せて2025年10月1日付で、小嶋範孝(こじま のりたか)氏がGM & カントリーマネージャーとして就任したことをお知らせします。 proteanTecsは、チップおよび電子システム内部から取得されるDeep Data(ディープデータ)テレメトリを解析することで、製造から運用までのライフサイクル全体にわたり、信頼性・電力・性能を精緻にモニタリングできる最先端ソリューションを提供しています。これにより、設計、製造テストから実際の運用段階に至るまで、品質の向上、開発期間の短縮、そして予知保全を実現します。自動車、データセンター、通信分野のリーディングカンパニーからの信頼を受けて、世界的な半導体メーカー、システムメーカーによって既に実装が行われており、AIトレーニングやADAS(先進運転支援シス...
-
Brivo Unifies Intrusion Alarms and 24/7 Monitoring in Brivo Security Suite to Deliver Faster Threat Detection
BETHESDA, Md.--(BUSINESS WIRE)--Brivo, the global leader in cloud-native unified physical security, today announced a major expansion of the Brivo Security Suite, providing customers with enhanced tools to detect threats and accelerate response. The latest update unifies best-in-class intrusion alarms from Bosch and introduces a new Brivo Monitoring Service, creating a more comprehensive and straightforward physical security experience. “Our strategy is to deliver a unified, intelligent, and op...
-
ADDING and REPLACING Top Banking and Policy Leaders to Convene at KBRA’s Annual Bank Symposium 2025
NEW YORK--(BUSINESS WIRE)--Add after last paragraph of release: Registration Details The symposium will be held at the Willard InterContinental, located at 1401 Pennsylvania Avenue NW, Washington, D.C. Registration is closed to press and media. For more information and to register, please visit the registration page or contact events@kbra.com. See here for the agenda. The updated release reads: TOP BANKING AND POLICY LEADERS TO CONVENE AT KBRA’S ANNUAL BANK SYMPOSIUM 2025 KBRA is proud to host...
-
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eClinicalMedicine demonstrating that daily supplementation with Niagen®, Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient, significantly increased NAD+ levels and improved exe...